MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 413310 | Name: CP 100356

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CP 100356 is a specific inhibitor of MDR1 (P-Gp), the protypical ABC transporter. The compound has low uM to nM potency for inhibiting several MDR-1 substrates (calcein-AM, digoxin) in transfected MDCKII cells.

Chemical Structure

CP 100356
CP 100356
CAS#142716-85-6 (free base)

Theoretical Analysis

MedKoo Cat#: 413310

Name: CP 100356

CAS#: 142716-85-6 (free base)

Chemical Formula: C31H36N4O6

Exact Mass: 560.2635

Molecular Weight: 560.65

Elemental Analysis: C, 66.41; H, 6.47; N, 9.99; O, 17.12

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
142716-85-6 (free base) 142715-48-8(HCl)
Synonym
CP 100356; CP-100356; CP100356
IUPAC/Chemical Name
2-Quinazolinamine, 4-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-N-(2-(3,4-dimethoxyphenyl)ethyl)-6,7-dimethoxy-
InChi Key
PPMZZFZYBXDSRH-UHFFFAOYSA-N
InChi Code
InChI=1S/C31H36N4O6/c1-36-24-8-7-19(13-25(24)37-2)9-11-32-31-33-23-17-29(41-6)28(40-5)16-22(23)30(34-31)35-12-10-20-14-26(38-3)27(39-4)15-21(20)18-35/h7-8,13-17H,9-12,18H2,1-6H3,(H,32,33,34)
SMILES Code
COC1=CC2=NC(NCCC3=CC=C(OC)C(OC)=C3)=NC(N4CC5=C(C=C(OC)C(OC)=C5)CC4)=C2C=C1OC
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Solvent mg/mL mM
Solubility
Soluble in DMSO 0.0 100.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 560.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Toh S, Inoue S, Toda Y, Yuki T, Suzuki K, Hamamoto S, Fukatsu K, Aoki S, Uchida M, Asai E, Uozumi N, Sato A, Kinoshita T. Identification and Characterization of Compounds that Affect Stomatal Movements. Plant Cell Physiol. 2018 Aug 1;59(8):1568-1580. doi: 10.1093/pcp/pcy061. PMID: 29635388. 2: Zhao P, Kunze KL, Lee CA. Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes. Drug Metab Dispos. 2005 Jun;33(6):853-61. doi: 10.1124/dmd.104.002832. Epub 2005 Mar 2. PMID: 15743977. 3: Kalgutkar AS, Frederick KS, Chupka J, Feng B, Kempshall S, Mireles RJ, Fenner KS, Troutman MD. N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquino lin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a "chemical knock- out equivalent" to assess the impact of efflux transporters on oral drug absorption in the rat. J Pharm Sci. 2009 Dec;98(12):4914-27. doi: 10.1002/jps.21756. PMID: 19373887. 4: Li M, de Graaf IA, de Jager MH, Groothuis GM. Rat precision-cut intestinal slices to study P-gp activity and the potency of its inhibitors ex vivo. Toxicol In Vitro. 2015 Aug;29(5):1070-8. doi: 10.1016/j.tiv.2015.04.011. Epub 2015 Apr 25. PMID: 25917215. 5: Li M, de Graaf IA, van de Steeg E, de Jager MH, Groothuis GM. The consequence of regional gradients of P-gp and CYP3A4 for drug-drug interactions by P-gp inhibitors and the P-gp/CYP3A4 interplay in the human intestine ex vivo. Toxicol In Vitro. 2017 Apr;40:26-33. doi: 10.1016/j.tiv.2016.12.002. Epub 2016 Dec 7. PMID: 27939799. 6: van Veen HW, Margolles A, Müller M, Higgins CF, Konings WN. The homodimeric ATP-binding cassette transporter LmrA mediates multidrug transport by an alternating two-site (two-cylinder engine) mechanism. EMBO J. 2000 Jun 1;19(11):2503-14. doi: 10.1093/emboj/19.11.2503. PMID: 10835349; PMCID: PMC212756. 7: Taylor JC, Ferry DR, Higgins CF, Callaghan R. The equilibrium and kinetic drug binding properties of the mouse P-gp1a and P-gp1b P-glycoproteins are similar. Br J Cancer. 1999 Nov;81(5):783-9. doi: 10.1038/sj.bjc.6690764. PMID: 10555746; PMCID: PMC2374293. 8: Kajiji S, Dreslin JA, Grizzuti K, Gros P. Structurally distinct MDR modulators show specific patterns of reversal against P-glycoproteins bearing unique mutations at serine939/941. Biochemistry. 1994 May 3;33(17):5041-8. doi: 10.1021/bi00183a006. PMID: 8172879.